This site is intended for healthcare professionals
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers

Expert opinion

Read time: 60 mins
Last updated:10th Sep 2021
Published:10th Sep 2021

RET inhibitors are an exciting development in the fight against non-small cell lung cancer (NSCLC) and thyroid cancers. Watch our expert interviews:

  • Dr Alexander Drilon discusses the impact of RET inhibitors for NSCLC
  • Professor Lori Wirth introduces RET inhibitors in the management of thyroid cancers
  • Professor Fernando Lopez-Rios explains molecular testing for RET alterations

RET inhibitors in non-small cell lung cancer

Dr Alexander Drilon, the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, USA, discusses RET inhibitors as a treatment for non-small cell lung cancer (NSCLC).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

RET inhibitors in thyroid cancer

Professor Lori Wirth, Associate Professor of Medicine at Harvard Medical School and Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital, Boston, USA, discusses the use of RET inhibitors to treat thyroid cancers.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Molecular testing for RET alterations

Join Professor Fernando Lopez-Rios, a professor of Pathology and Molecular Pathology from Spain, to learn why it is important to test for rearranged during transfection (RET) gene alterations in patients with non-small cell lung cancer (NSCLC) and thyroid cancer.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: